JP2025508721A5 - - Google Patents
Info
- Publication number
- JP2025508721A5 JP2025508721A5 JP2024548378A JP2024548378A JP2025508721A5 JP 2025508721 A5 JP2025508721 A5 JP 2025508721A5 JP 2024548378 A JP2024548378 A JP 2024548378A JP 2024548378 A JP2024548378 A JP 2024548378A JP 2025508721 A5 JP2025508721 A5 JP 2025508721A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- genetically modified
- gene
- mutation
- flt3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263311707P | 2022-02-18 | 2022-02-18 | |
| US63/311,707 | 2022-02-18 | ||
| US202263426138P | 2022-11-17 | 2022-11-17 | |
| US63/426,138 | 2022-11-17 | ||
| PCT/US2023/062757 WO2023159136A2 (en) | 2022-02-18 | 2023-02-16 | Epitope engineering of cell-surface receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025508721A JP2025508721A (ja) | 2025-04-10 |
| JP2025508721A5 true JP2025508721A5 (https=) | 2026-02-25 |
Family
ID=85772792
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024548378A Pending JP2025508721A (ja) | 2022-02-18 | 2023-02-16 | 細胞表面受容体のエピトープ操作 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250170182A1 (https=) |
| EP (1) | EP4479419A2 (https=) |
| JP (1) | JP2025508721A (https=) |
| KR (1) | KR20240145485A (https=) |
| CN (1) | CN119095953A (https=) |
| AU (1) | AU2023222086A1 (https=) |
| CA (1) | CA3244527A1 (https=) |
| WO (1) | WO2023159136A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| WO2026073244A1 (en) | 2024-09-30 | 2026-04-02 | Ensoma, Inc. | Constructs for multi-lineage expression of therapeutic agents |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003003006A2 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
| KR20230156800A (ko) | 2015-03-03 | 2023-11-14 | 더 제너럴 하스피탈 코포레이션 | 변경된 PAM 특이성을 갖는 조작된 CRISPR-Cas9 뉴클레아제 |
| RS61907B1 (sr) * | 2015-04-06 | 2021-06-30 | Subdomain Llc | Polipeptidi koji sadrže de novo vezujući domen i njihova primena |
| WO2016164641A1 (en) * | 2015-04-08 | 2016-10-13 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| JP6799586B2 (ja) | 2015-08-28 | 2020-12-16 | ザ ジェネラル ホスピタル コーポレイション | 遺伝子操作ＣＲＩＳＰＲ−Ｃａｓ９ヌクレアーゼ |
| WO2021151073A2 (en) | 2020-01-24 | 2021-07-29 | The General Hospital Corporation | Unconstrained genome targeting with near-pamless engineered crispr-cas9 variants |
| JP2024530465A (ja) * | 2021-08-06 | 2024-08-21 | ウニバズィテート バーゼル | 細胞療法に使用するための識別可能な細胞表面タンパク質変異体 |
-
2023
- 2023-02-16 JP JP2024548378A patent/JP2025508721A/ja active Pending
- 2023-02-16 KR KR1020247028868A patent/KR20240145485A/ko active Pending
- 2023-02-16 CN CN202380022625.5A patent/CN119095953A/zh active Pending
- 2023-02-16 US US18/838,922 patent/US20250170182A1/en active Pending
- 2023-02-16 WO PCT/US2023/062757 patent/WO2023159136A2/en not_active Ceased
- 2023-02-16 CA CA3244527A patent/CA3244527A1/en active Pending
- 2023-02-16 AU AU2023222086A patent/AU2023222086A1/en active Pending
- 2023-02-16 EP EP23713525.6A patent/EP4479419A2/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017355218B2 (en) | Immunologically discernible cell surface variants for use in cell therapy | |
| JP2023026580A (ja) | 造血幹細胞の選択的除去と置換のための組成物と方法 | |
| CN113164589A (zh) | 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途 | |
| TW201827460A (zh) | 改善配對的ｔ細胞受體 | |
| JP2020529830A (ja) | 新規ｔ細胞受容体およびそれを用いた免疫療法 | |
| US20220042038A1 (en) | Nanotransposon compositions and methods of use | |
| JP2025508721A5 (https=) | ||
| US20220380776A1 (en) | Base editor-mediated cd33 reduction to selectively protect therapeutic cells | |
| JP7743407B2 (ja) | 抗Ｍｕｃ１組成物及び使用方法 | |
| JP2023528415A5 (https=) | ||
| EP4268831A2 (en) | Reducing cd33 expression to selectively protect therapeutic cells | |
| JP2025131704A (ja) | 遺伝子治療のためのコンディショニング方法 | |
| CN120225209A (zh) | 用于非遗传毒性细胞调理的组合物和方法 | |
| CN116724109A (zh) | 用于cd34基因修饰的组合物和方法 | |
| WO2021207274A2 (en) | Human immune cells genomically modified to express orthogonal receptors | |
| EP4126925A2 (en) | Chimeric antigen receptors targeting cd33 | |
| JP2023521410A (ja) | 大型のアデノウイルスペイロードの組み込み | |
| EP4476267A2 (en) | Chimeric antigen receptors binding steap1 | |
| JP2025508721A (ja) | 細胞表面受容体のエピトープ操作 | |
| EP3172325B1 (en) | Molecular constructs and uses thereof | |
| JP2022547866A (ja) | 同種異系細胞組成物と使用方法 | |
| TW202118778A (zh) | Ｔ細胞受體及其使用方法 | |
| JP2026501695A (ja) | Ｋｉｔ細胞表面受容体のエピトープ操作 | |
| WO2025090985A1 (en) | Compositions comprising chimeric antigen receptors targeting citrullinated vimentin and methods of use thereof | |
| WO2025235408A1 (en) | Compositions comprising scfv sequences targeting cancer antigens and methods of use thereof |